Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
BHVN Price and Sentiment
BHVN Latest news
Biohaven (BHVN) Q3 Nurtec Preliminary Sales Top Expectations
2021-10-06 19:20Biohaven's (BHVN) sole marketable drug, Nurtec ODT reports preliminary sales for the third quarter, which beat expectations.
Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment
2021-10-05 07:30NEW HAVEN, Conn., Oct. 5, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Biohaven (BHVN) Phase III Multiple System Atrophy Study Fails
2021-09-28 11:36Biohaven's (BHVN) myeloperoxidase enzyme inhibitor, verdiperstat fails to statistically differentiate from placebo in improving disease progression in patients with multiple system atrophy in a late-stage study.
Why Are Biohaven Shares Trading Lower On Monday?
2021-09-27 09:31Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has announced results from a focused analysis of verdiperstat trial in verdiperstat in multiple system atrophy (MSA). Verdiperstat did not differ statistically from placebo on the prespecified primary efficacy measure or the key secondary efficacy measures.
Biohaven Provides Update On Phase 3 Trial And Multiple System Atrophy (MSA) Program
2021-09-27 07:00NEW HAVEN, Conn., Sept. 27, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Spotlights Nurtec® ODT (rimegepant), the only dual-therapy indicated for both the acute and preventive treatment of migraine, at the 2021 International Headache Society - European Headache Federation Joint Congress
2021-09-09 07:30NEW HAVEN, Conn., Sept. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Why Is Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 21.7% Since Last Earnings Report?
2021-09-08 13:16Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago.
Tuesday Afternoon Analyst Upgrades and Downgrades: SmileDirectClub, Squarespace, Victoria's Secret and More
2021-08-10 12:56With the trading day more than halfway over, the broad markets were mixed yet again, but this came with a couple of record highs.
Biohaven (BHVN) Q2 Earnings Miss, Nurtec Uptake Still Strong
2021-08-09 13:53Biohaven's (BHVN) sole approved drug, Nurtec ODT for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.
Biohaven Pharmaceutical Holding Company's (BHVN) CEO Vlad Coric on Q2 2021 Results - Earnings Call Transcript
2021-08-09 13:53Biohaven Pharmaceutical Holding Company's (BHVN) CEO Vlad Coric on Q2 2021 Results - Earnings Call Transcript